Brain TumorNCT02956291

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors

A study testing Magnetic Resonance Fingerprinting in people with Brain Tumor, run by Case Comprehensive Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Brain Tumor
What is being tested?: Magnetic Resonance Fingerprinting
Type of treatment: Injection or infusion, Medical device
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 170 participants
Where: 1 siteUnited States
Study dates: 15 Feb 2017to 17 Apr 2025
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosis of intra-axial brain tumor at initial diagnosis or patients with known treated brain tumors on follow-up with concern for imaging progression
Ability to understand and the willingness to sign a written informed consent document, or, in cases where the patient may have cognitive impairment, consent by a legal authorized representative or power of attorney
Patients with brain metastases undergoing partial brain radiation (gamma knife or SRS) with ability to undergo research scan at baseline, 1 month and , 3 months, and 6 months

Who cannot join

Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
The presence of an implanted pacemaker or implanted defibrillator device.
Patients with contraindications for MRI due to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient.
Pregnancy. Regular clinical practice already excludes pregnant patients from gadolinium contrast.
Implanted medical device not described above that is not MRI-compatible.
Known history of severe claustrophobia.
Prisoners and members of other vulnerable populations will be excluded from this study. The subject selection population will not regularly include prisoners and other vulnerable population members as these populations will not provide any additional unique information to or uniquely benefit from the study. Non-English speaking population will be excluded from the study due to lack of sufficient resources to pay for translator and interpreter services.
Minors will be excluded.

Trial locations and contacts

1 site in 1 country.

United States1 site

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106

Other trials in United States

About this study

The purpose of the research study is to test new methods that could improve diagnosis and assessment of brain tumors. One of these methods is a new MR (magnetic resonance) imaging technique called magnetic resonance fingerprinting (MRF), which allows for rapidly scanning the patient and provides quantitative information on tumor tissue. The investigators will compare the data gathered from MR Fingerprinting with other imaging tests, clinical information, treatment details and biopsy results to evaluate the accuracy of this new technique.

Read the detailed description

The primary objective of this study is to 1) evaluate the utility of quantitative MRI imaging including 3D-MRF in differentiating among different brain tumors and differentiating recurrent brain tumor (TR) from treatment effects

Secondary objectives include evaluating the correlation between quantitative MRI imaging with histopathological characteristics and genetic markers in pre-therapy setting and with treatment response and clinical outcomes in post treatment setting.

GROUP 1: All patients with newly diagnosed intra-axial brain neoplasms undergo volumetric MRI study with contrast for surgical planning or clinical diagnosis. Diffusion, diffusion tensor imaging and perfusion imaging are often performed as a part of standard clinical imaging. In addition to these acquisitions, the research 3D-MRF acquisition through the entire tumor will be acquired. The imaging parameters will be correlated individually and in combination with biopsy/ resection outcomes.

GROUP 2: All patients with brain tumors who present at post therapy follow up with imaging progression undergo serial imaging as a part of clinical care. The research 3D-MRF acquisitions will be added to these clinical scans. All the quantitative parameters will be evaluated individually and in combination to differentiate post treatment changes from tumor recurrence.

Conditions: Brain Tumor
Being tested: Magnetic Resonance Fingerprinting
Keywords: glioma, brain tumor, brain metastasis
Medical subject headings: Brain Neoplasms, Glioma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Magnetic Resonance FingerprintingDevice
Also called MRF, 3D-MRF, MRF relaxometry
Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes

Study groups in NCT02956291
Study group	Role	What they receive
Newly Diagnosed Brain Tumors	Experimental	Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence. Receives: Device: Magnetic Resonance Fingerprinting
Treated tumors with possible recurrence	Experimental	Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team. Receives: Device: Magnetic Resonance Fingerprinting

What is being measured

The primary outcome is the main question the study is designed to answer.

T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Tumor Type
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T1 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T2 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T1 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T2 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minuets after beginning study)
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Glioma Tumor Grade
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)

Secondary outcomes (2)

T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for IDH1 Mutations in Glioma Tumor
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for ATRX Mutations in Glioma Tumor
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Measured: At end of scan (45 minutes after beginning study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 Feb 201717 Apr 2025

First posted7 Nov 2016 (estimated)
Study start15 Feb 2017
Primary completion17 Apr 2025
Study completion17 Apr 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Brain TumorStudies of the same condition, open and under way.
More trials run by Case Comprehensive Cancer CenterThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Diagnosis
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 170 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02956291
Sponsor's protocol ID: CASE8316
Status last verified: Jul 2026
First submitted: 31 Oct 2016
Last updated: 25 Aug 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: Yes

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Active, not recruitingPhase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Glioblastoma, Recurrent Glioblastoma
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
RecruitingPhase 2/3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer

All Brain Tumor trials

Study at a glance

From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors
ClinicalTrials.gov ID: NCT02956291
Acronym / sponsor ID: CASE8316
Conditions: Brain Tumor
Keywords: glioma, brain tumor, brain metastasis
Study type: Interventional
Recruitment status: Completed
Enrolment: 170 participants (actual)
Lead sponsor: Case Comprehensive Cancer CenterUniversity, hospital or other
Study start: 15 Feb 2017 (actual)
Primary completion: 17 Apr 2025 (actual)
Study completion: 17 Apr 2025 (actual)
First posted: 7 Nov 2016 (estimated)
Results: Posted 25 Aug 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Diagnosis
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Newly Diagnosed Brain Tumors	Experimental	Device: Magnetic Resonance FingerprintingParticipants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
Treated tumors with possible recurrence	Experimental	Device: Magnetic Resonance FingerprintingParticipants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Diagnosis of intra-axial brain tumor at initial diagnosis or patients with known treated brain tumors on follow-up with concern for imaging progression
Ability to understand and the willingness to sign a written informed consent document, or, in cases where the patient may have cognitive impairment, consent by a legal authorized representative or power of attorney
Patients with brain metastases undergoing partial brain radiation (gamma knife or SRS) with ability to undergo research scan at baseline, 1 month and , 3 months, and 6 months

Key exclusion criteria (8 listed)

Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
The presence of an implanted pacemaker or implanted defibrillator device.
Patients with contraindications for MRI due to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient.
Pregnancy. Regular clinical practice already excludes pregnant patients from gadolinium contrast.
Implanted medical device not described above that is not MRI-compatible.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Magnetic Resonance FingerprintingAlso: MRF, 3D-MRF, MRF relaxometryNon-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes	Device	Newly Diagnosed Brain Tumors, Treated tumors with possible recurrence

Primary outcome

T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Tumor Type
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T1 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T2 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T1 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T2 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Time frame: At end of scan (45 minuets after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Glioma Tumor Grade
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Time frame: At end of scan (45 minutes after beginning study)
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.

2 secondary outcomes

T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for IDH1 Mutations in Glioma Tumor
Time frame: At end of scan (45 minutes after beginning study)
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for ATRX Mutations in Glioma Tumor
Time frame: At end of scan (45 minutes after beginning study)

Results and safety

Results posted to the registry on 25 Aug 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Experimental: Total Number of Scans	170	149

Primary outcome: T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type

Time frame: At end of scan (45 minutes after beginning study). Mean (Standard Deviation). Unit: Milliseconds (ms)

Measure	Experimental: Total Number of Scans n = 78
Group A: High Grade Glioma	1774.57 (204.54)
Group B: Low Grade Glioma	1908.31 (273.65)
Group C: Brain Metastasis	1722.56 (197.25)

Population analysed: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, and 39 participants had prior treatment, therefore of the 170 participants in the baseline population, only 78 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.

Primary outcome: T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type

Time frame: At end of scan (45 minutes after beginning study). Mean (Standard Deviation). Unit: Milliseconds (ms)

Measure	Experimental: Total Number of Scans n = 78
Group A: High Grade Glioma	98.88 (20.95)
Group B: Low Grade Glioma	114.07 (30.67)
Group C: Brain Metastasis	87.59 (28.01)

Primary outcome: T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Tumor Type

Time frame: At end of scan (45 minutes after beginning study). Mean (Standard Deviation). Unit: Milliseconds (ms)

Measure	Experimental: Total Number of Scans n = 51
Group A: High Grade Glioma	974.03 (309.57)
Group B: Low Grade Glioma	1558.47 (324.97)
Group C: Brain Metastasis	833.57 (238.65)

Population analysed: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 27 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 51 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.

Primary outcome: T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type

Time frame: At end of scan (45 minutes after beginning study). Mean (Standard Deviation). Unit: Milliseconds (ms)

Measure	Experimental: Total Number of Scans n = 51
Group A: High Grade Glioma	88.23 (20.75)
Group B: Low Grade Glioma	109.205 (39.63)
Group C: Brain Metastasis	86.43 (26.13)

Population analysed: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 27 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 51 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Up to 6 months. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Experimental: Total Number of Scans	0 of 170 (0%)	0 of 170 (0%)	0 of 170

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Brain Tumor

RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Active, not recruitingPhase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Glioblastoma, Recurrent Glioblastoma
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
RecruitingPhase 2/3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Chaitra A Badve, MD principal investigator

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Magnetic Resonance Fingerprinting in people with Brain Tumor, run by Case Comprehensive Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type (time frame: At end of scan (45 minutes after beginning study)). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02956291.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.